Market closed
Gilead Sciences/$GILD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Ticker
$GILD
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
18,000
Website
Gilead Sciences Metrics
BasicAdvanced
$114B
Market cap
109.20
P/E ratio
$0.84
EPS
0.20
Beta
$3.06
Dividend rate
3.36%
Dividend yield
Price and volume
Market cap
$114B
Beta
0.2
52-week high
$90.50
52-week low
$62.07
Average daily volume
5.3M
Dividend rate
$3.06
Financial strength
Current ratio
1.004
Quick ratio
0.69
Long term debt to equity
118.371
Total debt to equity
128.318
Dividend payout ratio (TTM)
366.03%
Interest coverage (TTM)
10.93%
Management effectiveness
Return on assets (TTM)
11.54%
Return on equity (TTM)
5.26%
Valuation
Price to earnings (TTM)
109.197
Price to revenue (TTM)
4.112
Price to book
6.25
Price to tangible book (TTM)
-8.88
Price to free cash flow (TTM)
17.199
Dividend yield (TTM)
3.34%
Forward dividend yield
3.36%
Growth
Revenue change (TTM)
1.54%
Earnings per share change (TTM)
-80.70%
3-year revenue growth (CAGR)
1.44%
3-year earnings per share growth (CAGR)
-40.99%
3-year dividend per share growth (CAGR)
3.03%
What the Analysts think about Gilead Sciences
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.
Gilead Sciences Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Gilead Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Gilead Sciences News
AllArticlesVideos
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
Benzinga·12 hours ago
Gilead's Stock Surge: What's Fueling the Momentum?
MarketBeat·14 hours ago
Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year
Seeking Alpha·18 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Market closed
Upcoming events
Dec
13
Gilead Sciences
Dividend·Ex-dividend
Dec
30
Gilead Sciences
Dividend·Payment
$0.77
Per share
FAQs
What’s the current market cap for Gilead Sciences stock?
Gilead Sciences (GILD) has a market cap of $114B as of November 08, 2024.
What is the P/E ratio for Gilead Sciences stock?
The price to earnings (P/E) ratio for Gilead Sciences (GILD) stock is 109.2 as of November 08, 2024.
Does Gilead Sciences stock pay dividends?
Yes, the Gilead Sciences (GILD) stock pays dividends to shareholders. As of November 08, 2024, the dividend rate is $3.06 and the yield is 3.36%. Gilead Sciences has a payout ratio of 366.03% on a trailing twelve-month basis.
When is the next Gilead Sciences dividend payment date?
The next Gilead Sciences (GILD) dividend payment is scheduled for December 30, 2024.
What is the beta indicator for Gilead Sciences?
Gilead Sciences (GILD) has a beta rating of 0.2. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.